Blog Archives

FDA-cleared genomic profiling tests to guide cancer treatment

December 25, 2017 – The American Food & Drug Administration (FDA) has approved two genetic tests to identify genetic alterations in tumors.  The FoundationOne CDx (F1CDx) genomic test and the MSK-IMPACT Tumor Profiling test both can help to guide physicians in clinical trial enrollment and in cancer treatment.

Read more ›

Tags: , , , , , , , ,

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD)

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type of white blood cells called histiocytes,

Read more ›

Tags: , , , , , , , , ,

Cobimetinib (Cotellic) is now approved as part of a combination treatment with Vemurafenib (Zelboraf) for advanced melanoma

November 13, 2015 – The American Food and Drug Administration (FDA) just approved Cobimetinib (Cotellic) to be used in combination with Vemurafenib (Zelboraf) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

Read more ›

Tags: , , , , , , , , , , , , , , ,

Can We Identify Risk for Drug Toxicity?

October 10, 2013 – Very recently, David Kerr, Professor of Cancer Medicine at University of Oxford, in the United Kingdom, and past President of the European Society for Medical Oncology, talked on Medscape (see the video here) about risk-benefit analyses for novel, inventive cancer treatments. See here in italics his statement:

 When we talk about precision medicine and personalized medicine,

Read more ›

Tags: , , , , , , , , , , , , ,

Dabrafenib [Tafinalar] and Trametinib [Mekinist] Approved for BRAF V600 Mutated Metastatic Melanoma

May 30, 2013 – From a Medscape News Release we learn today that two new drugs have been approved by the US Food and Drug Administration (FDA) for use in certain patients with metastatic or unresectable melanoma, along with a diagnostic test to identify patients who are suitable for treatment.

Read more ›

Tags: , , , , , , ,

Patients on Vemurafenib [Zelboraf] Need Testing for RAS Mutations: Secondary Cancers a Major Concern

January 26, 2012 – A January 20, 2012 article in Medscape Medical New illustrates how personalized medicine can be tricky. The case is Vemurafenib [Zelboraf], which was introduced to the market together with an companion genetic test mid 2011 for the treatment of advanced melanoma in suitable BRAF mutation (V600E) positive patients only.

Read more ›

Tags: , , , , , , ,

Vemurafenib [Zelboraf] Approved Together with a Companion Diagnostic Test by FDA for Advanced Melanoma in BRAF V600E Positive Patients

August 17, 2011 — The US Food and Drug Administration (FDA) has just approved the oral targeted therapy Vemurafenib [Zelboraf] for the first-line treatment of both metastatic and unresectable melanomas. The drug is specifically indicated for patients with melanoma whose tumors have V600E mutations in the BRAF gene. An estimated 50% of patients with melanoma have this type of BRAF mutation,

Read more ›

Tags: , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Spinal muscular atrophy (SMA): Newborn screening promises a benefit April 6, 2020
    On behalf of the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether it is meaningful to test newborns in Germany for spinal muscular atrophy (SMA) in combination with earlier diagnosis and treatment. The Institute's final report is now available.
  • Alport syndrome severity can be predicted by causative protein genotype April 6, 2020
    A Japanese research team has successfully developed a system to predict the severity of Alport syndrome, a serious hereditary kidney disease that occurs in about 1 out of 5,000 people in the US. Patients with Alport syndrome have abnormalities in the causative protein, type IV collagen, that often lead to chronic renal dysfunction requiring dialysis. […]
  • Research: Hereditary mutation drives aggressive head and neck, lung cancers in Asian population April 6, 2020
    Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have uncovered a genetic variant in a gene called MET that is responsible for more aggressive growth of head and neck, and lung cancers. A further probe into the finding revealed therapeutic strategies that could potentially target this […]
  • New insights into the genetic risk factors and disease pathways of multiple sclerosis April 6, 2020
    Multiple sclerosis (MS) is a debilitating disease in which the body's own immune system attacks itself and can, over time, permanently destroy the protective sheaths, or myelin, around nerve fibers in the brain. Myelin insulates nerve cells and facilitates the transmission of messages along them. When the myelin sheath is damaged, the nerves themselves may […]
  • Findings in mice reveal possibilities for fetal drug therapy for deafness April 6, 2020
    New research led by hearing scientists at Oregon Health & Science University suggests an avenue to treat and prevent intractable genetic disorders before birth.
  • Magnetoacoustic waves: Towards a new paradigm of on-chip communication April 6, 2020
    Researchers have observed directly and for the first time magnetoacoustic waves (sound-driven spin waves), which are considered as potential information carriers for novel computation schemes. These waves have been generated and observed on hybrid magnetic/piezoelectric devices. The experiments were designed by a collaboration between the University of Barcelona (UB), the Institute of Materials Science of […]
  • An updated overview of the complex clinical spectrum of tourette syndrome April 6, 2020
    Background: Tourette syndrome is a common nerve development disorder which is characterized by a variety of muscle or vocal movements called 'tics', often involuntary. The disorder is reflectively and quite erroneously associated by many as a just syndrome with tics and the frequent use of undesirable language (swearing). However, Tourette syndrome is a complex neuropsychiatric […]
  • Oil spill: where and when will it reach the beach? Answers to prevent environmental impacts April 6, 2020
    When an accident involving oil spills occurs, forecasting the behaviour of the oil slick and understanding in advance where and when it will reach the coastline is crucial to organize an efficient emergency response that is able to limit environmental and economic repercussions. A study led by CMCC Foundation's researchers, based on the concrete case […]
  • Which healthy lifestyle factors associated with more years free of chronic disease? April 6, 2020
    What combination of healthy lifestyle factors were associated with the most years lived without chronic diseases was the focus of this analysis that included data from more than 100,000 adults who were participants in 12 European studies.
  • Leaving its mark: How frailty impacts the blood April 6, 2020
    Fifteen blood metabolites are key for diagnosing the age-related disorder, frailty, new study finds.
Top